: Merck and Ridgeback Biotherapeutics to appeal advisory panel to EU regulator’s decision to recomme

Merck & Co. Inc. MRK and privately held Ridgeback Biotherapeutics said Friday a panel advising the European regulator has recommended refusing the marketing authorization for their jointly developed COVID antiviral for the treatment of certain adults. The companies said they would appeal the decision and request a review of the opinion, which was offered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. The antirival, called Lagevrio or...